Smoldering multiple myeloma: prevalence and current evidence guiding treatment decisions

IF 3.9 Q2 ONCOLOGY

Blood and Lymphatic Cancer-Targets and Therapy Pub Date : 2018-04-20 DOI:10.2147/BLCTT.S136447

Agnieszka Blum, D. Bazou, P. O’gorman

引用次数: 9

Abstract

Smoldering multiple myeloma (SMM) is an asymptomatic plasma cell proliferative disorder associated with risk of progression to symptomatic multiple myeloma (MM) or amyloidosis. In comparison to monoclonal gammopathy of undetermined significance (MGUS), SMM has a much higher risk of progression to MM. Thanks to advances in our understanding of the risk factors, the subset of patients with ultra-high risk of progression to MM (80%–90% at 2 years) has been identified. The revision of the diagnostic criteria resulted in changes in the management of this cohort of patients. In contrast to the management guidelines for MGUS patients, SMM patients need to be studied more intensively in order to identify biomarkers necessary for accurate risk stratification. In this review, we focus on the risk of progression from SMM to MM, as well as the influence of early treatment on overall survival, time to progression and quality of life.

查看原文本刊更多论文

阴燃型多发性骨髓瘤:患病率和指导治疗决策的现有证据

阴燃型多发性骨髓瘤(SMM)是一种无症状浆细胞增生性疾病，与进展为症状性多发性骨髓瘤(MM)或淀粉样变的风险相关。与未确定意义的单克隆γ病(MGUS)相比，SMM发展为MM的风险要高得多。由于我们对风险因素的理解有所进步，已经确定了发展为MM的超高风险患者亚群(2年内80%-90%)。诊断标准的修订导致这组患者的管理发生了变化。与MGUS患者的管理指南相反，SMM患者需要进行更深入的研究，以确定准确风险分层所需的生物标志物。在这篇综述中，我们关注从SMM到MM进展的风险，以及早期治疗对总生存期、进展时间和生活质量的影响。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Blood and Lymphatic Cancer-Targets and Therapy ONCOLOGY-

自引率

7.10%

发文量

审稿时长

16 weeks

期刊介绍： Blood and Lymphatic Cancer: Targets and Therapy is an international, peer reviewed, open access journal focusing on blood and lymphatic cancer research, identification of therapeutic targets, and the optimal use of preventative and integrated treatment interventions to achieve improved outcomes, enhanced survival, and quality of life for the cancer patient. Specific topics covered in the journal include: Epidemiology, detection and screening Cellular research and biomarkers Identification of biotargets and agents with novel mechanisms of action Optimal clinical use of existing anticancer agents, including combination therapies Radiation, surgery, bone marrow transplantation Palliative care Patient adherence, quality of life, satisfaction Health economic evaluations.